AxoGen (NASDAQ:AXGN) Sets New 1-Year High – Should You Buy?

AxoGen, Inc. (NASDAQ:AXGN)’s stock price reached a new 52-week high during trading on Thursday . The company traded as high as $19.03 and last traded at $18.89, with a volume of 457510 shares traded. The stock had previously closed at $18.97.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th.

AxoGen Stock Down 3.0 %

The stock has a market capitalization of $798.31 million, a P/E ratio of -56.69 and a beta of 1.01. The firm’s fifty day moving average is $15.64 and its 200-day moving average is $13.41. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67.

Hedge Funds Weigh In On AxoGen

A number of institutional investors have recently modified their holdings of AXGN. Calamos Advisors LLC acquired a new position in shares of AxoGen during the fourth quarter worth approximately $523,000. R Squared Ltd bought a new stake in shares of AxoGen during the fourth quarter worth approximately $30,000. SG Americas Securities LLC raised its stake in shares of AxoGen by 34.4% during the fourth quarter. SG Americas Securities LLC now owns 21,763 shares of the medical equipment provider’s stock worth $359,000 after buying an additional 5,576 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of AxoGen by 2,912.3% during the third quarter. JPMorgan Chase & Co. now owns 549,000 shares of the medical equipment provider’s stock worth $7,697,000 after buying an additional 530,775 shares during the last quarter. Finally, Principal Financial Group Inc. bought a new stake in shares of AxoGen during the third quarter worth approximately $207,000. 80.29% of the stock is owned by institutional investors.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.